上海三毛(600689.SH):預計所持創新壹號基金份額應確認公允價值變動損失為3203.6萬元
格隆匯 12 月 29日丨上海三毛(600689.SH)公佈,因創新壹號基金公允價值發生重大變化,出於謹慎性原則,公司擬對所持創新壹號基金份額的公允價值進行調整。鑑於仲裁裁決的執行進展不明朗,公司通過原核心股東回購創新壹號基金股權以收回投資面臨時間週期及收回金額難以準確預估的問題。因此,公司在假設原核心股東回購無法得到執行的前提下,以創新壹號基金向第三方出售股權可能獲得的現金金額進行測算,預計公司所持創新壹號基金份額應確認公允價值變動損失為3203.6萬元,扣除已在2019年度確認的公允價值變動損失519.01萬元後,本年擬確認的公允價值變動損失為2684.59萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.